Dual-target EZH2 inhibitor: latest advances in medicinal chemistry

被引：2
|
作者：
Wei, Lai [1 ,2 ,3 ]
Mei, Dan [1 ,2 ,3 ]
Hu, Sijia [1 ,2 ,3 ]
Du, Shufang [1 ,2 ,3 ]
机构：
[1] Sichuan Univ, West China Hosp, State Key Lab Oral Dis, Stomatol Dept Orthodont, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, Natl Ctr Stomatol, Chengdu 610041, Sichuan, Peoples R China
[3] Sichuan Univ, Natl Clin Res Ctr Oral Dis, Chengdu 610041, Sichuan, Peoples R China
来源：
FUTURE MEDICINAL CHEMISTRY | 2024年 / 16卷 / 15期
关键词：
AR; BMI1; DNMTs; drug design; EHMT2 (G9a); EZH2; inhibitors; structure-activity relationship; SMALL-MOLECULE INHIBITOR; GROUP PROTEIN EZH2; HOMOLOG; EZH2; ANDROGEN RECEPTOR; STEM-CELLS; SELECTIVE-INHIBITION; CANCER-CELLS; POLYCOMB; METHYLATION; COMPLEX;
D O I：
10.1080/17568919.2024.2380243
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, plays a crucial role in tumor progression by regulating gene expression. EZH2 inhibitors have emerged as promising anti-tumor agents due to their potential in cancer treatment strategies. However, single-target inhibitors often face limitations such as drug resistance and side effects. Dual-target inhibitors, exemplified by EZH1/2 inhibitor HH-2853(28), offer enhanced efficacy and reduced adverse effects. This review highlights recent advancements in dual inhibitors targeting EZH2 and other proteins like BRD4, PARP1, and EHMT2, emphasizing rational design, structure-activity relationships, and safety profiles, suggesting their potential in clinical applications.
引用
收藏
页码：1561 / 1582
页数：22
相关论文
共 50 条
  • [41] EZH2 is therapeutic target for personalized treatment in multiple myeloma
    Herviou, Laurie
    Cavalli, Giacomo
    Moreaux, Jerome
    BULLETIN DU CANCER, 2018, 105 (09) : 804 - 819
  • [42] EZH2 as a therapeutic target in glioblastoma: a cellular and molecular study
    de la Rosa, Javier
    Iraburu, Marta
    Gallo-Oller, Gabriel
    Urdiciain, Alejandro
    Fan, Xing
    Shahi, Mehdi H.
    Melendez, Barbara
    Rey, Juan A.
    Idoate, Miguel A.
    Castresana, Javier S.
    CANCER RESEARCH, 2017, 77
  • [43] Ezh2, a novel target in detection and therapy of breast cancer
    Pourakbar, Sarah
    Pluard, Timothy J.
    Accurso, Anthony D.
    Farassati, Faris
    ONCOTARGETS AND THERAPY, 2017, 10 : 2685 - 2687
  • [44] EZH2 Expression in Rhabdomyosarcoma: A Potential Biomarker and Therapeutic Target
    Wang, Qian
    Shapiro, Kate
    Lu, Yong
    Shroyer, Kenneth
    Hwang, Sonya
    MODERN PATHOLOGY, 2019, 32
  • [45] Identification of molecules that regulate the sensitivity of EZH2 inhibitor in neuroblastoma
    Endo, Yuki
    Takenobu, Hisanori
    Sugino, Ryuichi
    Haruta, Masayuki
    Mukae, Kyosuke
    Satoh, Shunpei
    Shinno, Yoshitaka
    Hasegawa, Mariko
    Okada, Ryu
    Katai, Yutaka
    Nio, Masaki
    Ohira, Miki
    Kamijo, Takehiko
    CANCER SCIENCE, 2018, 109 : 1176 - 1176
  • [46] First EZH2 Inhibitor Approved-for Rare Sarcoma
    Leslie, Mitch
    CANCER DISCOVERY, 2020, 10 (03) : 333 - 334
  • [47] THE EZH2 INHIBITOR TAZEMETOSTAT SHOWS EFFICACY IN FOLLICULAR LYMPHOMA
    不详
    CANCER DISCOVERY, 2020, 10 (12) : 1787 - 1787
  • [48] Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors
    Shinohara, Haruka
    Sawado, Rie
    Nakagawa, Makoto
    Hattori, Ayuna
    Yamagata, Kazutsune
    Tauchi, Kimiharu
    Ito, Jumpei
    Kuwahara, Yasumichi
    Okuda, Tsukasa
    Ogawa, Chitose
    Kitabayashi, Issay
    MOLECULAR THERAPY ONCOLYTICS, 2022, 27 : 14 - 25
  • [49] EZH2, a potential therapeutic target in Merkel cell carcinoma
    Durand, M.
    Mouchard, A.
    Esnault, C.
    Samimi, M.
    Kervarrec, T.
    Touze, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (10) : S191 - S191
  • [50] Dual targeting of CXCR4 and EZH2 in endometriosis
    Brunty, Sarah
    Wagner, Kassey
    Fleshman, Taylor
    Ruley, Morgan
    Mitchell, Brenda
    Santanam, Nalini
    ISCIENCE, 2025, 28 (04)
12345